ABSI vs CRL: stock comparison and AI forecast
Absci Corp (ABSI) and Charles River Laboratories International, Inc. (CRL) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
ABSI Absci Corp
- Price
- $10.00 +78.3% · 6M
- Market Cap
- $1.72B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
CRL Charles River Laboratories International, Inc.
- Market Cap
- $16.80B
- P/E Ratio
- –
- Size
- large-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- CRL is 9.8 times larger than ABSI by market capitalization ($16.80B against $1.72B).
- CRL turns -6.0% of its revenue into net income, against -2234.6% for ABSI.
- CRL carries 1.64 times debt per unit of equity, against 0.17 times for ABSI.
- Both companies share the SEC industry classification Services-Commercial Physical & Biological Research.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | ABSI | CRL |
|---|---|---|
| Market Cap | $1.72B | $16.80B |
| P/B Ratio | 8.63x | 5.92x |
| EPS | $-0.81 | $-4.00 |
| Book Value/Share | $1.16 | $59.48 |
| Revenue/Share | $0.01 | $83.77 |
| FCF/Share | $-0.63 | $7.76 |
Profitability & Margins
| Metric | ABSI | CRL |
|---|---|---|
| ROE | -53.0% | -8.4% |
| ROA | – | -3.2% |
| ROIC | – | 1.4% |
| Operating Margin | -2676.0% | 2.2% |
| Net Margin | -2234.6% | -6.0% |
| EBT Margin | -2567.4% | -0.9% |
| Tax Rate | 0.0% | -152.4% |
Financial Health
| Metric | ABSI | CRL |
|---|---|---|
| Current Ratio | 10.63x | 1.35x |
| Quick Ratio | – | 1.04x |
| D/E Ratio | 0.17x | 1.64x |
| Financial Leverage | – | 2.65x |
| Interest Coverage | -174.4x | 5.0x |
| Working Capital | $189M | $394M |
Cash Flow
| Metric | ABSI | CRL |
|---|---|---|
| Operating Cash Flow | -$108M | $582M |
| Free Cash Flow | -$109M | $371M |
| Capital Spending | -$890K | -$212M |
| OCF Growth YoY | – | -26.1% |
| FCF Growth YoY | – | -35.9% |
| FCF/Sales | -6981.0% | 9.3% |
| CapEx/Sales | 57.0% | 5.3% |
Operational Efficiency
| Metric | ABSI | CRL |
|---|---|---|
| Asset Turnover | – | 0.53x |
| Receivables Turnover | – | 5.6x |
| Fixed Assets Turnover | 0.1x | 2.7x |
| Days Sales Outstanding | – | 65 days |
Income Statement
| Metric | ABSI | CRL |
|---|---|---|
| Total Revenue | $2M | $4.00B |
| Operating Income | -$126M | $90M |
| Net Income | -$105M | -$238M |
| R&D Expense | $86M | – |
| SG&A Expense | $35M | $762M |
Dividend & Shareholder Information
| Metric | ABSI | CRL |
|---|---|---|
| Shares Outstanding | 172M | 48M |
ABSI vs CRL: stock comparison and AI forecast
Which is bigger, ABSI or CRL?
CRL is 9.8 times larger than ABSI by market capitalization ($16.80B against $1.72B).
Which one does Intratio's AI model rank higher, ABSI or CRL?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.